These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 22212574

  • 1. Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'?
    Foster GR, Serfaty LD.
    Liver Int; 2012 Feb; 32 Suppl 1():61-3. PubMed ID: 22212574
    [Abstract] [Full Text] [Related]

  • 2. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A, Serfaty L.
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [Abstract] [Full Text] [Related]

  • 3. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P, Reddy KR.
    Antivir Ther; 2011 Feb; 16(8):1187-201. PubMed ID: 22155901
    [Abstract] [Full Text] [Related]

  • 4. New treatments for chronic hepatitis C virus infection.
    Corouge M, Pol S.
    Med Mal Infect; 2011 Nov; 41(11):579-87. PubMed ID: 21764234
    [Abstract] [Full Text] [Related]

  • 5. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
    Barritt AS, Fried MW.
    Gastroenterology; 2012 May; 142(6):1314-1323.e1. PubMed ID: 22537438
    [Abstract] [Full Text] [Related]

  • 6. Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents.
    Woodrell C, Weiss J, Branch A, Gardenier D, Krauskopf K, Kil N, Paredes H, Bichoupan K, Sigel K.
    J Addict Med; 2015 May; 9(5):405-10. PubMed ID: 26291545
    [Abstract] [Full Text] [Related]

  • 7. Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C.
    Med Lett Drugs Ther; 2011 Jul 25; 53(1369):57-9. PubMed ID: 21778964
    [No Abstract] [Full Text] [Related]

  • 8. Protease inhibitors for hepatitis C: economic implications.
    Turner SJ, Brown J, Paladino JA.
    Pharmacoeconomics; 2013 Sep 25; 31(9):739-51. PubMed ID: 23839698
    [Abstract] [Full Text] [Related]

  • 9. Boceprevir for chronic HCV genotype 1 infection.
    Limaye AR, Draganov PV, Cabrera R.
    N Engl J Med; 2011 Jul 14; 365(2):176; author reply 177-8. PubMed ID: 21751914
    [No Abstract] [Full Text] [Related]

  • 10. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E.
    Antivir Ther; 2011 Jul 14; 16(5):695-704. PubMed ID: 21817191
    [Abstract] [Full Text] [Related]

  • 11. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
    Asselah T, Marcellin P.
    Liver Int; 2012 Feb 14; 32 Suppl 1():88-102. PubMed ID: 22212578
    [Abstract] [Full Text] [Related]

  • 12. The future for the treatment of genotype 4 chronic hepatitis C.
    Esmat G, El Raziky M, El Kassas M, Hassany M, Gamil ME.
    Liver Int; 2012 Feb 14; 32 Suppl 1():146-50. PubMed ID: 22212586
    [Abstract] [Full Text] [Related]

  • 13. Telaprevir for the treatment of chronic hepatitis C infection.
    Muir AJ.
    Expert Rev Anti Infect Ther; 2011 Dec 14; 9(12):1105-14. PubMed ID: 22114960
    [Abstract] [Full Text] [Related]

  • 14. A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.
    Maticic M, Luznik Z, Stepec S, Popovic P, Snedec N, Poljak M, Stanisavljevic D.
    J Clin Gastroenterol; 2014 Dec 14; 48(5):464-5. PubMed ID: 24275712
    [No Abstract] [Full Text] [Related]

  • 15. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
    Forestier N, Zeuzem S.
    Liver Int; 2012 Feb 14; 32 Suppl 1():44-50. PubMed ID: 22212571
    [Abstract] [Full Text] [Related]

  • 16. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
    Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF.
    Aliment Pharmacol Ther; 2012 Mar 14; 35(6):647-62. PubMed ID: 22296568
    [Abstract] [Full Text] [Related]

  • 17. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.
    Dusheiko G, Wedemeyer H.
    Gut; 2012 Dec 14; 61(12):1647-52. PubMed ID: 22936671
    [No Abstract] [Full Text] [Related]

  • 18. [Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
    Makara M, Horváth G, Gervain J, Pár A, Szalay F, Telegdy L, Tornai I, Ujhelyi E, Hunyady B.
    Orv Hetil; 2012 Mar 11; 153(10):375-94. PubMed ID: 22370225
    [Abstract] [Full Text] [Related]

  • 19. Optimal treatment with boceprevir for chronic HCV infection.
    Maasoumy B, Manns MP.
    Liver Int; 2013 Feb 11; 33 Suppl 1():14-22. PubMed ID: 23286841
    [Abstract] [Full Text] [Related]

  • 20. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP, Markova AA, Calle Serrano B, Cornberg M.
    Liver Int; 2012 Feb 11; 32 Suppl 1():27-31. PubMed ID: 22212568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.